Eli Lilly clinical miss has effects across pharma

The same drug development news that's hurting Eli Lilly shares might be good for Amgen and Sanofi-Regeneron.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.